Acetoacetic Acid

Acetoacetic Acid

SCHEMBL491475

CC(=O)CC(=O)O.CC(=O)CC(=O)O.OCC(O)CO

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.41
KDM6B O15054 1/20 0.41
KDM5C P41229 1/20 0.41
EGLN1 Q9GZT9 1/20 0.41
PHF8 Q9UPP1 1/20 0.41
KDM2A Q9Y2K7 1/20 0.41
LDHA P00338 1/20 0.38
SRR Q9GZT4 1/20 0.38
SLC22A6 Q4U2R8 1/20 0.38
OR51E2 Q9H255 1/20 0.36
SLC15A2 Q16348 1/20 0.36
MGAM O43451 1/20 0.35
GAA P10253 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35
TGFBR1 P36897 1/20 0.33
MAPT P10636 1/20 0.33
GABRR1 P24046 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetoacetic Acid SCHEMBL29155554 1.00 LMNA (0.45) LMNAALDH1A1KDM4EKDM6BKDM5C
Acetoacetic Acid SCHEMBL491497 1.00 LMNA (0.45) LMNAALDH1A1KDM4EKDM6BKDM5C
Acetoacetic Acid SCHEMBL648595 1.00 LMNA (0.45) LMNAALDH1A1KDM4EKDM6BKDM5C
Acetoacetic Acid SCHEMBL5795622 0.89 TGFBR1 (0.40) LMNAALDH1A1KDM4EKDM6BKDM5C
Glycerin SCHEMBL28122415 0.89 KDM4E (0.46) LMNAALDH1A1KDM4EKDM6BKDM5C
Acetoacetic Acid SCHEMBL2005043 0.89 KDM4E (0.37) LMNAALDH1A1KDM4EKDM6BKDM5C
Glycerin SCHEMBL28686701 0.87 ALDH1A1 (0.53) LMNAALDH1A1KDM4EKDM6BKDM5C
Acetoacetic Acid SCHEMBL27153879 0.87 THRB (0.54) LMNAALDH1A1KDM4EKDM6BKDM5C
Acetoacetic Acid SCHEMBL28640192 0.85 TDP1 (0.50) LMNAALDH1A1KDM4EKDM6BKDM5C
Acetoacetic Acid SCHEMBL1058961 0.85 TDP1 (0.50) LMNAALDH1A1KDM4EKDM6BKDM5C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4574871-A1 CURABLE POLYMER COMPOSITIONS COMPRISING ALDIMINES, POLYISOCYANATES AND COMPOUNDS WITH ACTIVATED METHYLENE GROUPS Sika Technology AG (CH) 2025-06-25 EP claimed
EP-4574867-A1 CURABLE POLYMER COMPOSITIONS CONTAINING ISOCYANATES, ALDIMINES AND COMPOUNDS HAVING ACTIVATED METHYLENE GROUPS Sika Technology AG (CH) 2025-06-25 EP claimed
US-5420335-A Intravenous feeding BIRKHAHN RONALD H (US) 1995-05-30 US claimed
WO-1995009146-A1 PARENTERAL NUTRIENTS BASED ON WATER SOLUBLE GLYCEROL BISACETOACETATES EASTMAN CHEMICAL COMPANY (US) 1995-04-06 WO claimed
US-12622967-B2 Molecules, formulations, and methods for nutritional support of athletes, patients, and others TODAY, INC. (US) 2026-05-12 US disclosed
EP-4574871-A1 CURABLE POLYMER COMPOSITIONS COMPRISING ALDIMINES, POLYISOCYANATES AND COMPOUNDS WITH ACTIVATED METHYLENE GROUPS Sika Technology AG (CH) 2025-06-25 EP disclosed
EP-4574867-A1 CURABLE POLYMER COMPOSITIONS CONTAINING ISOCYANATES, ALDIMINES AND COMPOUNDS HAVING ACTIVATED METHYLENE GROUPS Sika Technology AG (CH) 2025-06-25 EP disclosed
US-20240299548-A1 MOLECULES, FORMULATIONS, AND METHODS FOR NUTRITIONAL SUPPORT OF ATHLETES, PATIENTS, AND OTHERS TODAY, INC. (US) 2024-09-12 US disclosed
US-12071498-B2 Radically polymerizable compositions Polynt Composites USA, Inc. (US) 2024-08-27 US disclosed
US-12023382-B2 Molecules, formulations, and methods for nutritional support of athletes, patients, and others Today Inc. (US) 2024-07-02 US disclosed
CN-113474383-B Free radical polymerizable composition 波林复合材料美国股份有限公司 2023-10-31 CN disclosed
US-20230257500-A1 RADICALLY POLYMERIZABLE COMPOSITIONS BNY MELLON CORPORATE TRUSTEE SERVICES LIMITED, AS SECURITY AGENT (GB) 2023-08-17 US disclosed
EP-1749845-A1 Composite materials and methods of making the same Rohm and Haas Company (US) 2007-02-07 EP disclosed
US-5693850-A REACTING SOLKETAL AND AN ACETOACETATE ESTER OR PRECURSOR TO PRODUCE AN INTERMEDIATE SOLKETAL ACETOACETATE DERIVATIVE AND REDUCING IN PRESENCE OF HYDROGEN AND HYDROGENATION CATALYST TO FORM SOLKETAL-BETA-HYDROXYBUTYRATE; PARENTERAL DIET EASTMAN CHEMICAL COMPANY (US) 1997-12-02 US disclosed
US-5420335-A Intravenous feeding BIRKHAHN RONALD H (US) 1995-05-30 US disclosed
US-5420335-A Intravenous feeding BIRKHAHN RONALD H (US) 1995-05-30 US disclosed
US-5420335-A Intravenous feeding BIRKHAHN RONALD H (US) 1995-05-30 US disclosed
WO-1995009144-A1 NUTRITIVE WATER SOLUBLE GLYCEROL ESTERS OF HYDROXY BUTYRIC ACID EASTMAN CHEMICAL COMPANY (US) 1995-04-06 WO disclosed
WO-1995009146-A1 PARENTERAL NUTRIENTS BASED ON WATER SOLUBLE GLYCEROL BISACETOACETATES EASTMAN CHEMICAL COMPANY (US) 1995-04-06 WO disclosed
WO-1995009146-A1 PARENTERAL NUTRIENTS BASED ON WATER SOLUBLE GLYCEROL BISACETOACETATES EASTMAN CHEMICAL COMPANY (US) 1995-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622967-B2 Molecules, formulations, and methods for nutritional support of athletes, patients, and others SLC2A9, GYS1, SLC2A8 LMNA 3333/4885ALDH1A1 350/4885KDM4E 1504/4885
US-20240299548-A1 MOLECULES, FORMULATIONS, AND METHODS FOR NUTRITIONAL SUPPORT OF ATHLETES, PATIENTS, AND OTHERS CPT1B, GK, CPT1A LMNA 1973/4885ALDH1A1 1249/4885KDM4E 3282/4885
US-12023382-B2 Molecules, formulations, and methods for nutritional support of athletes, patients, and others CPT1B, GK, CPT1A LMNA 1973/4885ALDH1A1 1249/4885KDM4E 3282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.